We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nonprofit Viral Diagnostics Center Launched in the United States

By LabMedica International staff writers
Posted on 07 Jul 2009
An American university and a global health care company have partnered to launch a nonprofit viral diagnostics center to help identify unknown viruses from around the world.

Among the center's initial projects is genetic sequencing of strains of the influenza A(H1N1) virus that emerged during spring, 2009. More...
The lab is collaborating with international scientists to compare strains found in patients in Mexico, the United States, and Canada, in an effort to identify how stable the virus is as it spreads. There is already concern that the virus, which shares a genetic fingerprint with other strains, could mutate to a more virulent and dangerous strain.

The University of California, San Francisco (UCSF; San Francisco, CA, USA) and its partner Abbott (Abbott Park, IL, USA) have launched the Viral Diagnostics and Discovery Center, (near the UCSF Mission Bay campus, CA, USA), which aims to expedite virus discovery in acute and chronic human illnesses, including outbreaks and rare and unusual diseases.

The center's technology is based on the ViroChip, a high-throughput screening technology that uses a DNA microarray to test viral samples. The ViroChip was developed by UCSF Professors Joe DeRisi, PhD, and Donald Ganem, MD, and was first used in the 2003 identification of the virus causing Severe Acute Respiratory Syndrome, or SARS.

"In the past two decades, many human diseases, including ulcers and cervical cancer, have been discovered to be caused by bacteria or viruses," said John Hackett, PhD, manager of Abbott's Virus Discovery Program, who led Abbott's efforts to create the new center. "This center could prove to be a powerful partnership for detecting more infectious agents, leading to the development of new diagnostics and therapeutics.

Related Links:

University of California, San Francisco
Abbott
Viral Diagnostics and Discovery Center



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Hematology Consumables
Bioblood Devices
New
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.